Efficacy of an Alpha-Blocker for the Treatment of Nonneurogenic Voiding Dysfunction in Women: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial
4
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the efficacy of an alpha-1 adrenergic receptor (α1-AR) blocker for the treatment of female voiding dysfunction (FVD) through a pressure-flow study. Methods: This was a randomized, double-blind, placebo-controlled trial. Women aged ≥18 years with voiding symptoms, as defined by an American Urological Association symptom score (AUA-SS) ≥15 and a maximum flow rate (Qmax) <15 mL/ sec with a voided volume of >100 mL and/or a postvoid residual (PVR) volume >150 mL, were randomly allocated to either the alfuzosin or placebo group. After 8 weeks of treatment, changes in the AUA-SS, Bristol female lower urinary tract symptoms (BFLUTS) questionnaire, Qmax/PVR, and voiding diary were compared between groups. Patients’ satisfaction with the treatment was compared. Patients were categorized into 3 groups according to the Blaivas-Groutz bladder outlet obstruction (BOO) nomogram: none, mild, and moderate to severe. Subgroup comparisons were also made. Results: Of a total of 187 women, 154 (79 alfuzosin, 75 placebo) were included in the analysis. After 8 weeks of treatment, the AUA-SS decreased by 7.0 in the alfuzosin group and by 8.0 in the placebo group. Changes in AUA-SS subscores, BFLUTS (except the I-sum), the voiding diary, and Qmax/PVR were not significantly different between groups. Approximately 54% of the alfuzosin group and 62% of the placebo group were satisfied with the treatment. No significant difference was observed between groups according to the presence or grade of BOO. Conclusions: Alfuzosin might not be more effective than placebo for treating FVD. The presence or the grade of BOO did not affect the results. A further study with sufficient power is needed to determine the efficacy of α1-AR blockers for the treatment of FVD.
Abstract
Purpose: To evaluate the efficacy of an alpha-1 adrenergic receptor (α1-AR) blocker for the treatment of female voiding dysfunction (FVD) through a pressure-flow study. Methods: This was a randomized, double-blind, placebo-controlled trial. Women aged ≥18 years with voiding symptoms, as defined by an American Urological Association symptom score (AUA-SS) ≥15 and a maximum flow rate (Qmax) <15 mL/ sec with a voided volume of >100 mL and/or a postvoid residual (PVR) volume >150 mL, were randomly allocated to either the alfuzosin or placebo group. After 8 weeks of treatment, changes in the AUA-SS, Bristol female lower urinary tract symptoms (BFLUTS) questionnaire, Qmax/PVR, and voiding diary were compared between groups. Patients’ satisfaction with the treatment was compared. Patients were categorized into 3 groups according to the Blaivas-Groutz bladder outlet obstruction (BOO) nomogram: none, mild, and moderate to severe. Subgroup comparisons were also made. Results: Of a total of 187 women, 154 (79 alfuzosin, 75 placebo) were included in the analysis. After 8 weeks of treatment, the AUA-SS decreased by 7.0 in the alfuzosin group and by 8.0 in the placebo group. Changes in AUA-SS subscores, BFLUTS (except the I-sum), the voiding diary, and Qmax/PVR were not significantly different between groups. Approximately 54% of the alfuzosin group and 62% of the placebo group were satisfied with the treatment. No significant difference was observed between groups according to the presence or grade of BOO. Conclusions: Alfuzosin might not be more effective than placebo for treating FVD. The presence or the grade of BOO did not affect the results. A further study with sufficient power is needed to determine the efficacy of α1-AR blockers for the treatment of FVD.
참고문헌 (20)
- Haylen BT, "An International Urogynecological Association (IUGA)", International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction, 2010, pp.29, 4~20
- Patel R, "Bladder outlet obstruction in women: prevalence, recognition, and management", Curr Urol Rep, 2, pp.379~387 (2001)[DOI]
- Haylen BT, "Has the true prevalence of voiding difficulty in urogynecology patients been underestimated?", Int Urogynecol J Pelvic Floor Dysfunct, 18, pp.53~56 (2007)[DOI]
- Irwin DE, "Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study", Eur Urol, 50, pp.1306~1314 (2006)[DOI]
- Lee YS, "Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms: results of Korean EPIC study", World J Urol, 29, pp.185~190 (2011)[DOI]
- Canda AE, "Pharmacologic targets on the female urethra", Urol Int, 80, pp.341~354 (2008)[DOI]
- Andersson KE, "Prostatic alpha 1-adrenoceptors and uroselectivity", Prostate, 30, pp.202~215 (1997)[DOI]
- Pummangura N, "Efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in women", Asian J Surg, 30, pp.131~137 (2007)[DOI]
- Low BY, "Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial", J Urol, 179, pp.1461~1469 (2008)[DOI]
- 이규성, "Efficacy and Safety of Tamsulosin for the Treatment of Non-neurogenic Voiding Dysfunction in Females: A 8-Week Prospective Study", Journal of Korean Medical Science, 25(1), pp.117~122 (2010), 대한의학회
- Choi HR, "Translation validity and reliability of I-PSS Korean version", Korean J Urol, 37, pp.659~665 (1996)
- Oh SJ, "Translation and linguistic validation of Korean version of the Bristol female lower urinary tract symptom instrument", J Korean Continence Soc, 8, pp.89~113 (2004)[DOI]
- Brookes ST, "A scored form of the Bristol female lower urinary tract symptoms questionnaire: data from a randomized controlled trial of surgery for women with stress incontinence", Am J Obstet Gynecol, 191, pp.73~82 (2004)[DOI]
- Matza LS, "Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ)", Neurourol Urodyn, 24, pp.215~225 (2005)[DOI]
- Blaivas JG, "Bladder outlet obstruction nomogram for women with lower urinary tract symptomatology", Neurourol Urodyn, 19, pp.553~564 (2000)[DOI]
- Roehrborn CG, "Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies", BJU Int, 92, pp.257~261 (2003)[DOI]
- Lepor H, "Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatismlike symptoms", J Urol, 154, pp.116~118 (1995)[DOI]
- Choi YS, "Analysis of female voiding dysfunction: a prospective, multi-center study", Int Urol Nephrol, 45, pp.989~994 (2013)[DOI]
- Scarpero HM, "American Urological Association Symptom Index for lower urinary tract symptoms in women: correlation with degree of bother and impact on quality of life", Urology, 61, pp.1118~1122 (2003)[DOI]
- Groutz A, "The significance of the American Urological Association symptom index score in the evaluation of women with bladder outlet obstruction", J Urol, 163, pp.207~211 (2000)[DOI]